Floatz logo

Ladiratuzumab Vedotin

HER2 Positive Breast Neoplasms

Seagen Inc.antibody_drug_conjugatePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

187 Active assets in the HER2 Positive Breast Neoplasms cohort.

Asset / SponsorPhaseRating
Vinorelbine
Jazz Pharmaceuticals
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
Epirubicin
Shanghai JMT-Bio Inc.
Phase 3BB
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BB
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB

View all 50 →

Same molecule, other indications

Ladiratuzumab Vedotin is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
angiosarcomaDormant
CCC
Indicative ·
53 / 100
View asset →
Hormone Receptor Positive TumorDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →